Researchers tracked nearly 2 million purchases. New GLP-1 users shifted toward fewer calories and less sugar, though the per-item changes were small.
Recap by typeshit. Full story at MindBodyGreen.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Takashi Miki tells HCPLive the effect didn't need immune iNKT cells, and suggests pairing GLP-1 drugs with PPARα activators for fatty liver disease.
A projection framing weight loss drugs as a growing slice of American healthcare spending. Thin on detail beyond the market forecast.
Loading…